Coor Service Management Holding AB (STO:COOR)
Sweden · Delayed Price · Currency is SEK 47.50
+1.40 (3.04%)
Aug 1, 2025, 5:29 PM CET
Inozyme Pharma Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Revenue | 12,386 | 12,439 | 12,443 | 11,789 | 10,104 | 9,591 | Upgrade |
Revenue Growth (YoY) | -1.75% | -0.03% | 5.55% | 16.68% | 5.35% | -7.00% | Upgrade |
Cost of Revenue | 10,948 | 11,013 | 11,108 | 10,488 | 8,899 | 8,566 | Upgrade |
Gross Profit | 1,438 | 1,426 | 1,335 | 1,301 | 1,205 | 1,025 | Upgrade |
Selling, General & Admin | 1,009 | 979 | 886 | 832 | 774 | 679 | Upgrade |
Operating Expenses | 1,009 | 979 | 886 | 832 | 774 | 679 | Upgrade |
Operating Income | 429 | 447 | 449 | 469 | 431 | 346 | Upgrade |
Interest Expense | -159 | -164 | -127 | -67 | -53 | -57 | Upgrade |
Interest & Investment Income | 3 | 3 | 4 | 1 | 1 | 1 | Upgrade |
Currency Exchange Gain (Loss) | 6 | 1 | -1 | 2 | 1 | -2 | Upgrade |
Other Non Operating Income (Expenses) | -20 | -18 | -20 | -8 | -7 | -7 | Upgrade |
EBT Excluding Unusual Items | 259 | 269 | 305 | 397 | 373 | 281 | Upgrade |
Other Unusual Items | -75 | -75 | -85 | -61 | -29 | -29 | Upgrade |
Pretax Income | 184 | 194 | 220 | 336 | 344 | 252 | Upgrade |
Income Tax Expense | 65 | 68 | 65 | 79 | 79 | 61 | Upgrade |
Earnings From Continuing Operations | 119 | 126 | 155 | 257 | 265 | 191 | Upgrade |
Net Income | 119 | 126 | 155 | 257 | 265 | 191 | Upgrade |
Net Income to Common | 119 | 126 | 155 | 257 | 265 | 191 | Upgrade |
Net Income Growth | -33.89% | -18.71% | -39.69% | -3.02% | 38.74% | 13.02% | Upgrade |
Shares Outstanding (Basic) | 95 | 95 | 95 | 95 | 95 | 95 | Upgrade |
Shares Outstanding (Diluted) | 95 | 95 | 95 | 95 | 95 | 95 | Upgrade |
Shares Change (YoY) | -0.02% | 0.13% | -0.18% | -0.07% | -0.26% | -0.20% | Upgrade |
EPS (Basic) | 1.25 | 1.32 | 1.63 | 2.70 | 2.78 | 2.00 | Upgrade |
EPS (Diluted) | 1.25 | 1.32 | 1.63 | 2.70 | 2.78 | 2.00 | Upgrade |
EPS Growth | -33.88% | -18.81% | -39.56% | -2.88% | 39.00% | 13.21% | Upgrade |
Free Cash Flow | 482 | 250 | 551 | 638 | 703 | 692 | Upgrade |
Free Cash Flow Per Share | 5.07 | 2.63 | 5.80 | 6.71 | 7.38 | 7.25 | Upgrade |
Dividend Per Share | 1.000 | 1.000 | 2.400 | 2.400 | 2.400 | 2.000 | Upgrade |
Dividend Growth | -58.33% | -58.33% | - | - | 20.00% | - | Upgrade |
Gross Margin | 11.61% | 11.46% | 10.73% | 11.04% | 11.93% | 10.69% | Upgrade |
Operating Margin | 3.46% | 3.59% | 3.61% | 3.98% | 4.27% | 3.61% | Upgrade |
Profit Margin | 0.96% | 1.01% | 1.25% | 2.18% | 2.62% | 1.99% | Upgrade |
Free Cash Flow Margin | 3.89% | 2.01% | 4.43% | 5.41% | 6.96% | 7.22% | Upgrade |
EBITDA | 592 | 601 | 636 | 696 | 690 | 609 | Upgrade |
EBITDA Margin | 4.78% | 4.83% | 5.11% | 5.90% | 6.83% | 6.35% | Upgrade |
D&A For EBITDA | 163 | 154 | 187 | 227 | 259 | 263 | Upgrade |
EBIT | 429 | 447 | 449 | 469 | 431 | 346 | Upgrade |
EBIT Margin | 3.46% | 3.59% | 3.61% | 3.98% | 4.27% | 3.61% | Upgrade |
Effective Tax Rate | 35.33% | 35.05% | 29.54% | 23.51% | 22.96% | 24.21% | Upgrade |
Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.